- Home
- SND vs IFRX Comparison
SND vs IFRX Comparison
Compare SND & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SND
- IFRX
- Stock Information
- Founded
- SND 2011
- IFRX 2007
- Country
- SND United States
- IFRX Germany
- Employees
- SND N/A
- IFRX N/A
- Industry
- SND Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- SND Industrials
- IFRX Health Care
- Exchange
- SND Nasdaq
- IFRX Nasdaq
- Market Cap
- SND 104.7M
- IFRX 122.5M
- IPO Year
- SND 2016
- IFRX 2017
- Fundamental
- Price
- SND $2.42
- IFRX $2.08
- Analyst Decision
- SND Hold
- IFRX Strong Buy
- Analyst Count
- SND 2
- IFRX 1
- Target Price
- SND $2.63
- IFRX $8.00
- AVG Volume (30 Days)
- SND 256.7K
- IFRX 290.3K
- Earning Date
- SND 11-12-2024
- IFRX 11-08-2024
- Dividend Yield
- SND N/A
- IFRX N/A
- EPS Growth
- SND N/A
- IFRX N/A
- EPS
- SND N/A
- IFRX N/A
- Revenue
- SND $281,956,000.00
- IFRX $187,930.00
- Revenue This Year
- SND N/A
- IFRX $311.47
- Revenue Next Year
- SND N/A
- IFRX $227.11
- P/E Ratio
- SND N/A
- IFRX N/A
- Revenue Growth
- SND N/A
- IFRX 177.12
- 52 Week Low
- SND $1.65
- IFRX $1.17
- 52 Week High
- SND $2.80
- IFRX $2.44
- Technical
- Relative Strength Index (RSI)
- SND 58.28
- IFRX 67.84
- Support Level
- SND $2.26
- IFRX $1.51
- Resistance Level
- SND $2.37
- IFRX $2.15
- Average True Range (ATR)
- SND 0.15
- IFRX 0.25
- MACD
- SND -0.00
- IFRX 0.05
- Stochastic Oscillator
- SND 45.71
- IFRX 62.50
About SND Smart Sand Inc.
Smart Sand Inc is a fully integrated frac sand supply and services company that offers complete mine-to-well site proppant supply and logistics solutions. It produces Northern White frac sand, which is a premium proppant used to enhance hydrocarbon recovery rates in the hydraulic fracturing of oil and natural gas wells. Its product portfolio includes Smart System, which includes SmartBelt, SmartDepot Silo and SmartPath Loader. The company caters its products and services to oil and natural gas exploration and production companies and oilfield service companies. The majority of its revenue comes from Sand Sales, followed by logistics.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.